Nasus Pharma NSRX
NYSE NSRX
$3.38 +0.13 (+4.20%)
As of: Oct 21, 2026 · 2:12 PM EDT

Nasus Pharma (NSRX) Current Deferred Revenue (2025 - 2026)

Updated

Analysis

Nasus Pharma (NSRX) Current Deferred Revenue (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.71 Bn 1,105.29 Bn 19.71 Bn
2 Johnson & Johnson 617.55 Bn 536.07 Bn 17.26 Bn
3 AbbVie 501.02 Bn 474.13 Bn 12.70 Bn
4 Merck 368.18 Bn 322.56 Bn 12.21 Bn
5 Novartis Ag 297.89 Bn 261.88 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 236.60 Bn 191.99 Bn 7.24 Bn
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn
9 Pfizer 169.77 Bn 116.42 Bn 10.94 Bn
10 Nasus Pharma 27.03 Mn 10.33 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 54,000.00
Dec 31, 2025 45,000.00
API Access

Nasus Pharma Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NSRX&period=max&api_key=YOUR_API_KEY